Everolimus in Patients with Autosomal Dominant Polycystic Kidney Disease

2010574 citationsJournal Articlebronze Open Access

Authors

Gerd Walz · University Medical Center Freiburg

Klemens Budde · Charité - Universitätsmedizin Berlin

Marwan Mannaa · Centre Virchow-Villermé

Jens Nürnberger · University of Duisburg-Essen

Christoph Wanner · Universitätsklinikum Würzburg

Claudia Sommerer · University Hospital Heidelberg

Ulrich Kunzendorf

Abstract

Within the 2-year study period,as compared with placebo, everolimus slowed the increase in total kidney volume of patients with ADPKD but did not slow the progression of renal impairment [corrected]. (Funded by Novartis; EudraCT number, 2006-001485-16; ClinicalTrials.gov number, NCT00414440.)

Topics & Keywords

Genetic and Kidney Cyst Diseases Renal and related cancers Biomedical Research and Pathophysiology

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 363, Issue 9, pp. 830-840

DOI: 10.1056/nejmoa1003491

Field-Weighted Citation Impact: 29.73